China Securities Regulatory Commission issued the Audit Committee Board 2016 77th issuance examination committee meeting held on May 18, in which West Point Jilin Pharmaceutical Technology Development Co., Ltd. first application has not been adopted as the third year of the IPO is not enterprise. Investment bank analysts pointed out that since 2016 overall I would rate is still high, but prevents "sick listing" is still the regulatory focus. It is worth noting that the last two months, the weekly number of enterprises will be reduced from 6 to 4, slowing down the rhythm will feature.
A Couple of Nav Changes
-
FEEDI wanted to bring everyone’s attention to a couple of important website
changes. The first one has to do with menus on Slope…………. For years, the
act of...
No comments:
Post a Comment